Zacks Asks If CAH Is Undervalued; DeepValue Analysis Says No

What happened

A recent Zacks article questions whether Cardinal Health (CAH) is undervalued, highlighting its strong earnings momentum and guidance raises. However, DeepValue's master report assigns a 'POTENTIAL SELL' rating, arguing the stock at ~$214 trades at 22x non-GAAP EPS and 17.8x EV/EBITDA with no margin of safety. The report flags deteriorating earnings quality, as GAAP EPS of $6.45 trails non-GAAP $8.24 due to $464M in amortization, while rising interest expense and negative book equity undermine balance sheet strength. Customer concentration (CVS at 30% of revenue) and IRA-driven drug pricing risks create asymmetric downside if growth merely normalizes. Consequently, the current valuation embeds optimistic assumptions that are unlikely to be sustained, making the stock overvalued rather than undervalued.

Implication

Investors should trim or avoid CAH above ~$210, as the risk/reward skews negative over the next 6-18 months. The specialty/MSO story is real but overhyped, and the widening GAAP/non-GAAP gap, rising leverage, and CVS concentration leave little room for error. A re-entry near $185 or after clearer FY27 visibility offers a better setup.

Thesis delta

The narrative has shifted from potential undervaluation to clear overvaluation. The DeepValue analysis exposes that CAH's earnings growth is acquisition-dependent and non-GAAP, with rising interest costs and policy risks that the market is ignoring. The stock's momentum and guidance hikes have created a crowded, high-expectation setup with limited upside and material downside.